Bomedemstat

Extended indication	Essential thrombocythaemia and myelofibrosis.
Therapeutic value	No estimate possible yet
Registration phase	Clinical trials

Product

Active substance	Bomedemstat
Domain	Hematology
Reason of inclusion	New medicine (specialité)
Main indication	Myeloproliferative disorders
Extended indication	Essential thrombocythaemia and myelofibrosis.
Manufacturer	Imago
Route of administration	Oral
Therapeutical formulation	Capsule
Budgetting framework	Intermural (MSZ)
Additional remarks	Lysine specific demethylase 1 inhibitor.

Therapeutic value	No estimate possible yet
Frequency of administration	1 times a day
References	NCT05223920

Patient volume	< 166 Market share is generally not included unless otherwise stated.
References	NKR 2018 (1);
Additional remarks	In totaal waren er 166 diagnoses in 2018 (1).

Patient volume

< 166

Market share is generally not included unless otherwise stated.

References

NKR 2018 (1);

Additional remarks

In totaal waren er 166 diagnoses in 2018 (1).

There is currently nothing known about the expected cost.

There is currently nothing known about the possible total cost.

There is currently nothing known about off label use.

There is currently nothing known about indication extensions.

There is currently no futher information available.